One more shot at slowing Keytruda’s first-line lung cancer domination

After the recent failure of Astrazeneca’s Mystic study investors following developments in first-line lung cancer have one further key event to look forward to this year: a US approval decision over Roche’s Tecentriq combined with Avastin and chemotherapy.